share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'SAB Biotherapeutics Is Pursuing IND and CTA Filings With U.S. FDA and EMA in 2024 to Clinically Advance Development of SAB-142 Into Phase 2b Study'

Benzinga ·  Nov 29, 2023 07:00
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'SAB Biotherapeutics Is Pursuing IND and CTA Filings With U.S. FDA and EMA in 2024 to Clinically Advance Development of SAB-142 Into Phase 2b Study'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment